KFBIO Closes on Series B Funding Round

作者: Mailman 2020-04-07 09:02
江丰生物
http://www.kfbio.cn/
企业数据由 动脉橙 提供支持
数字病理系统开发及设备生产商 | C轮 | 运营中
中国-浙江
2022-07-12
融资金额:RMB¥1亿
盛山资产
查看

According to PEdaily.cn, Ningbo Konfoong Bioinformation Tech Co., Ltd. ("KFBIO"), an innovative company of artificial intelligence (AI) in digital pathology, has closed a Series B round of financing, with a total amount of funding rounds over 100 million RMB. The latest financing is led by Intel Capital, with participation from Zhejiang Newline Media Investment and Yinxinggu Capital.


Proceeds of this round will be used for the development and launch of KFBIO's AI pathology-based products, the expansion of overseas markets, and the upgrading of the cloud pathology platform.


Founded in 2011, KFBIO is a total solution provider of pathology related products which include sample processing equipment, digital pathology scanning systems, pathology information system and DL algorithms/models for detecting and classifying precancerous changes and abnormalities. Holding more than 200 patents, KFBIO has the ability to provide intelligent solutions for pathology.


KFBIO is a member of the Intel® AI Builders Program. In 2018, Intel and KFBIO jointly established the laboratory focusing on the research and development of AI-powered pathological applications. By 2019, great results have been achieved -- the automated cervical cancer cell screening system was born in the laboratory, which can improve the efficiency by more than 50 times compared with the existing system. The deep learning-based screening assisted diagnostic system of cervical cancer has provided the cervical cancer screening service for hundreds of thousands of women.


>>>>

About Intel Capital


Intel Capital is a strategic investment program of Intel Corporation, and a global commitment aimed at investing in the future of disruption. Since 1991, Intel Capital has invested US$12.4 billion in 1,544 companies in 57 countries worldwide, and 670 portfolio companies have gone public or been acquired.


>>>>
About Zhejiang Newline Media Investment


Zhejiang Newline Media Investment directly manages and operates assets of over 2 billion yuan. According to the risk assessment and benefit requirements, the company invests actively in the cultural media, emerging industries, consumer goods, modern services, and financial fields.

相关赛道 医疗信息化
如果您想对接动脉网所报道的企业,请填写表单,我们的工作人员将征求企业意见后,尽快为您服务。
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近100+细分领域,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Yizhun Intelligent Closes on ¥100 million Series B Funding Round

DEEP INFORMATICS++ Closes ¥100M Series B Funding Round

Lead Medical Snares ¥10M in Series A2 Financing

Imsight Technology Raises ¥10M in a New Round of Financing

Mailman

共发表文章3242篇

最近内容
  • 一分钟看懂谷歌、苹果、亚马逊、微软数字健康布局

    2022-01-01

  • 动脉橙产业智库发布《2020全球数字健康产业发展趋势展望》

    2020-08-27

  • Glyscend Therapeutics完成2050万美元A轮融资,用于开发针对T2D代谢性疾病的新型口服聚合物类疗法

    2020-06-17

上一篇

Cytovant Sciences Announces $23.5 Million Financing Led by BNH Investment

2020-04-07
下一篇

Genechem Completes ¥400M Series C Financing, To Accelerate the Development of Innovative Medical Products

2020-04-07